Hims & Hers adds injectable and oral testosterone therapies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men’s Health Launch to Date
October 21, 2026 8:20 AM EDTNew injectable and oral options offer eligible men more ways to get proactive about their testosterone health
SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the launch of new injectable and oral testosterone replacement therapies (TRT) for eligible men. Its the largest expansion of the companys mens health program since first introducing the category last September, giving eligible men more options to treat low testosterone in partnership with licensed providers through Hims.
This press release... More



